BullFrog AI Holdings (BFRG) Non Operating Interest Expenses (2022 - 2026)
BullFrog AI Holdings' (BFRG) quarterly Non Operating Interest Expenses came in at $2373.0 in Q2 2026, down 3.1% on a YoY basis from $2449.0 in Q2 2025, and up 281.51% quarter-over-quarter from $622.0 in Q4 2025.
Analysis
BullFrog AI Holdings (BFRG) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends
BullFrog AI Holdings (BFRG) has reported Non Operating Interest Expenses for 5 consecutive years, with $2373.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Interest Expenses fell 3.1% year-over-year to $2373.0; the trailing twelve-month figure through Jun 2026 stood at $6987.0 (down 33.14% YoY), and the FY2025 full-year result was $5629.0, down 69.0% from the prior year.
- Non Operating Interest Expenses grew to $2373.0 in Q2 2026 per BFRG's latest filing, from $622.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $124159.0 in Q3 2022 and bottomed at $622.0 in Q4 2025.
- Historically, Non Operating Interest Expenses has averaged $26611.4 across 5 years, with a median of $4978.0 in 2024.
- The widest YoY moves for Non Operating Interest Expenses: up 265.58% in 2023, down 98.04% in 2023.
- Over 5 years, Non Operating Interest Expenses stood at $112477.0 in 2022, then tumbled by 98.04% to $2209.0 in 2023, then retreated by 9.1% to $2008.0 in 2024, then sank by 69.02% to $622.0 in 2025, then surged by 281.51% to $2373.0 in 2026.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $2373.0, $622.0, and $1543.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 20.27 Mn |
| 10 | BullFrog AI Holdings | 9.27 Mn | 2.35 Mn | 106,899.00 | 2,373.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,373.00 |
| Dec 31, 2025 | 622.00 |
| Sep 30, 2025 | 1,543.00 |
| Jun 30, 2025 | 2,449.00 |
| Mar 31, 2025 | 1,015.00 |
| Dec 31, 2024 | 2,008.00 |
| Sep 30, 2024 | 4,978.00 |
| Jun 30, 2024 | 7,899.00 |
| Mar 31, 2024 | 3,273.00 |
| Dec 31, 2023 | 2,209.00 |
| Sep 30, 2023 | 5,758.00 |
| Jun 30, 2023 | 10,841.00 |
| Mar 31, 2023 | 60,281.00 |
| Dec 31, 2022 | 112,477.00 |
| Sep 30, 2022 | 124,159.00 |
| Jun 30, 2022 | 94,020.00 |
| Mar 31, 2022 | 16,489.00 |